A microfluidic platform for the characterisation of membrane active antimicrobials

Journal Article (2019)
Author(s)

K. Al Nahas (Cavendish Laboratory)

J. Cama (Cavendish Laboratory)

M. Schaich (Cavendish Laboratory)

K. Hammond (National Physical Laboratory)

S. Deshpande (Kavli institute of nanoscience Delft, TU Delft - BN/Cees Dekker Lab, TU Delft - QN/Quantum Nanoscience)

C. Dekker (TU Delft - BN/Cees Dekker Lab, TU Delft - QN/Quantum Nanoscience, Kavli institute of nanoscience Delft)

M. G. Ryadnov (National Physical Laboratory)

U. F. Keyser (Cavendish Laboratory)

DOI related publication
https://doi.org/10.1039/c8lc00932e Final published version
More Info
expand_more
Publication Year
2019
Language
English
Issue number
5
Volume number
19
Pages (from-to)
837-844
Downloads counter
323
Collections
Institutional Repository
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

The spread of bacterial resistance against conventional antibiotics generates a great need for the discovery of novel antimicrobials. Polypeptide antibiotics constitute a promising class of antimicrobial agents that favour attack on bacterial membranes. However, efficient measurement platforms for evaluating their mechanisms of action in a systematic manner are lacking. Here we report an integrated lab-on-a-chip multilayer microfluidic platform to quantify the membranolytic efficacy of such antibiotics. The platform is a biomimetic vesicle-based screening assay, which generates giant unilamellar vesicles (GUVs) in physiologically relevant buffers on demand. Hundreds of these GUVs are individually immobilised downstream in physical traps connected to separate perfusion inlets that facilitate controlled antibiotic delivery. Antibiotic efficacy is expressed as a function of the time needed for an encapsulated dye to leak out of the GUVs as a result of antibiotic treatment. This proof-of-principle study probes the dose response of an archetypal polypeptide antibiotic cecropin B on GUVs mimicking bacterial membranes. The results of the study provide a foundation for engineering quantitative, high-throughput microfluidics devices for screening antibiotics.